5 results on '"Raimon Sanmarti"'
Number of results to display per page
Search Results
2. Reacciones adversas relacionadas con la administración de inhibidores del TNF. Análisis de un registro de terapias biológicas
- Author
-
Paloma Vela Casasempere, Loreto Carmona, Carmen Tenorio, Basilio Rodríguez-Diez, Raimon Sanmarti, Agustí Sellas, María Victoria Hernández, Cristina Hidalgo Calleja, Antonio Naranjo Hernandez, Eduardo Collantes Estévez, Beatriz Pérez-Zafrilla, Miguel A. Descalzo, and Enrique Casado
- Subjects
Rheumatology - Abstract
Objetivo: Estimar la frecuencia de aparicion de las reacciones relacionadas con la administracion (RRA), los sintomas asociados a las graves o tardias, la ventana de exposicion desde inicio de la terapia biologica y si hay diferencias entre infliximab, etanercept y adalimumab. Pacientes y metodo: BIOBADASER es un registro de acontecimientos adversos establecido en 2001 para determinar la seguridad de las terapias biologicas en enfermedades reumaticas. Contiene datos de los pacientes, tratamiento y acontecimientos adversos relevantes. Resultados: Se registro un total de 496 RRA relevantes en 442 pacientes, lo que representa un 19,6% (496/2.531) de todos los acontecimientos adversos comunicados y un 6,3% de los pacientes registrados (442/6.969). La tasa de incidencia de RRA por 1.000 anos-paciente con infliximab es de 28 casos (intervalo de confianza [IC] del 95%, 25-31), con etanercept 0,2 (IC del 95%, 0,1-0,4) y con adalimumab 0,2 (IC del 95%, 0,07-0,7). En mas de la mitad de las RRA, el acontecimiento adverso da lugar a la interrupcion del farmaco relacionado y en el 5% de los casos el paciente requiere ser hospitalizado. Mas del 20% de las RRA ocurren despues de 15 meses de tratamiento, incluso aparecen despues de 5 anos. En las reacciones adversas tardias los sintomas comunicados con mas frecuencia son erupciones, fiebre, malestar general y mialgias. Conclusiones: Las RRA pueden aparecer en cualquier momento de la enfermedad, son una de las causas mas frecuentes de interrupcion de tratamiento con infliximab. Aunque con menor frecuencia, tambien se relacionan con etanercept y adalimumab en sintomas que pueden no identificarse como tales
- Published
- 2008
- Full Text
- View/download PDF
3. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
- Author
-
Fleischmann, Roy, primary, Mysler, Eduardo, additional, Hall, Stephen, additional, Kivitz, Alan J, additional, Moots, Robert J, additional, Luo, Zhen, additional, DeMasi, Ryan, additional, Soma, Koshika, additional, Zhang, Richard, additional, Takiya, Liza, additional, Tatulych, Svitlana, additional, Mojcik, Christopher, additional, Krishnaswami, Sriram, additional, Menon, Sujatha, additional, Smolen, Josef S, additional, Adams, Luthando, additional, Ally, Mahmood M, additional, du Plooy, Maria C, additional, Louw, Ingrid C, additional, Nayiager, Savithree, additional, Nel, Christoffel B, additional, Nel, Debra, additional, Reuter, Helmuth, additional, Soloman, Ahmed S, additional, Spargo, Catherine E, additional, Rischmueller, Maureen, additional, Sharma, Shunil D, additional, Will, Robert K, additional, Youssef, Peter P, additional, Arroyo, Caroline, additional, Baes, Rosario P, additional, Dulos, Roger B, additional, Hao, Llewellyn T, additional, Lanzon, Allan E, additional, Lichauco, Juan Javier T, additional, Mangubat, Jill H, additional, Ramiterre, Edgar B, additional, Reyes, Bernadette Heizel M, additional, Tan, Perry P, additional, Choe, Jung-Yoon, additional, Kang, Young Mo, additional, Kwon, Seong Ryul, additional, Lee, Sang-Heon, additional, Lee, Shin-Seok, additional, Yoo, Dae-Hyun, additional, Lin, Hsiao-Yi, additional, Luo, Shue-Fen, additional, Tsai, Shih-Tzu, additional, Tsai, Wen-Chan, additional, Tseng, Jui-Cheng, additional, Wei, Cheng-Chung C, additional, Asavatanabodee, Paijit, additional, Nantiruj, Kanokrat, additional, Nilganuwong, Surasak, additional, Uea-Areewongsa, Parichat, additional, Majstorovic, Ljubinka Bozic, additional, Bacic, Suada Mulic, additional, Batalov, Anastas Z, additional, Georgieva-Slavcheva, Gabriela, additional, Mihailova, Mariyana, additional, Nikolov, Nikolay G, additional, Penev, Dimitar P, additional, Spasov, Yuliy A, additional, Stanimirova, Krasimira, additional, Todorov, Stoyan, additional, Toncheva, Antoaneta R, additional, Yordanova, Nadezhda, additional, Mosterova, Zdenka, additional, Novosad, Libor, additional, Prochazkova, Leona, additional, Stehlikova, Helena, additional, Stejfova, Zuzana, additional, Kiseleva, Natalia, additional, Pank, Lea, additional, Savi, Triin, additional, Alexandra, Balbir-Gurman, additional, Amital, Howard, additional, Mevorach, Dror, additional, Rosner, Itzhak A, additional, Mihailova, Anna, additional, Stumbra-Stumberga, Evija, additional, Basijokiene, Vida, additional, Lietuvininkiene, Virginija, additional, Unikiene, Dalia, additional, Brzezicki, Jan, additional, Dudek, Anna M, additional, Glowacka-Kulesz, Maria B, additional, Grabowicz-Wasko, Barbara, additional, Hajduk-Kubacka, Sabina, additional, Hilt, Joanna, additional, Hrycaj, Pawel, additional, Jeka, Slawomir, additional, Kolasa, Renata, additional, Krogulec, Marek, additional, Mastalerz, Hanna, additional, Olak-Popko, Anna, additional, Owczarek, Elzbieta, additional, Ruzga, Zofia, additional, Walczak, Alina, additional, Ancuta, Codrina I, additional, Ancuta, Ioan, additional, Balanescu, Andra R, additional, Berghea, Florian, additional, Bojin, Silvia, additional, Arvunescu, Mihaela A Ianuli, additional, Ionescu, Ruxandra M, additional, Mociran, Eugenia, additional, Pavel, Mariana, additional, Rednic, Simona, additional, Voie, Adriana, additional, Zainea, Carmen M, additional, Bugrova, Olga V, additional, Demin, Alexander, additional, Ershova, Olga B, additional, Gavrisheva, Inna A, additional, Krechikova, Diana G, additional, Kuropatkin, Gennady V, additional, Marusenko, Irina M, additional, Menshikova, Irina V, additional, Noskov, Sergey M, additional, Rebrov, Andrey P, additional, Smakotina, Svetlana A, additional, Yakushin, Sergey S, additional, Zhilyaev, Evgeny, additional, Ramos, Juan Jose Amarelo, additional, Garcia, Francisco Javier Blanco, additional, Nebro, Antonio Fernandez, additional, Esteban, Silvia Perez, additional, Burson, Juan Miguel Sanchez, additional, Sala, Raimon Sanmarti, additional, Ataman, Sebnem, additional, Hizmetli, Sami, additional, Kuru, Omer, additional, Douglas, Karen M, additional, Emery, Paul, additional, Ong, Voon H, additional, Sheeran, Thomas P, additional, Faraawi, Rafat Y, additional, Lessard, Clode, additional, Mendoza, Carlos Abud, additional, Avila-Armengol, Hilario Ernesto, additional, Zapata, Francisco I Avila, additional, Irazoque-Palazuelos, Fedra Consuelo, additional, Cecena, Marco Antonio Maradiaga, additional, Pacheco-Tena, Cesar F, additional, Rizo-Rodriguez, Juan C, additional, Rodriguez-Torres, Isaura M, additional, Aelion, Jacob A, additional, Caciolo, Barbara A, additional, Calmes, James M, additional, Chatpar, Prem, additional, Dayal, Nimesh, additional, De Jesus, Alex, additional, Dikranian, Ara H, additional, Diri, Erdal, additional, Fairfax, Michael J, additional, Fenton, Ira F, additional, Fleischmann, Roy M, additional, Gaylis, Norman B, additional, George, Ronald L, additional, Halter, Dale G, additional, Hernandez, Paul, additional, Hole, Susan A, additional, Hou, Antony C, additional, Huff, John P, additional, Kafaja, Suzanne, additional, Kennedy, Alastair C, additional, Kenney, Howard, additional, Kimmel, Steven C, additional, Kirby, Brian S, additional, Legerton, Clarence W, additional, Lindsey, Stephen M, additional, Mallepalli, Jyothi R, additional, Mathews, Steven D, additional, Metyas, Samy K, additional, Mizutani, Wesley T, additional, Najam, Sabeen, additional, Nascimento, Joao M, additional, Pang, Shirley W, additional, Patel, Rakesh C, additional, Poiley, Jeffrey E, additional, Ramirez, Carlos E, additional, Reddy, Riteesha, additional, Rehman, Qaiser, additional, Schnitz, William M, additional, Scoville, Craig D, additional, Shergy, William J, additional, Silverfield, Joel C, additional, Singhal, Atul K, additional, Smallwood-Sherrer, Yvonne R, additional, Songcharoen, Suthin N, additional, Stack, Michael T, additional, Stohl, William, additional, Su, Tien-I K, additional, Udell, James, additional, Waraich, Saleem, additional, Weidmann, Charles E, additional, Wei, Nathan, additional, Wiesenhutter, Craig W, additional, Winkler, Anne E, additional, Zagar, Karen E, additional, Berman, Alberto, additional, Mysler, Eduardo F, additional, Hidalgo, Rodolfo A Pardo, additional, Venarotti, Horacio O, additional, Sariego, Irmgadt Annelise Goecke, additional, Calabresse, Renato E Jimenez, additional, Ruiz-Tagle, Juan Ignacio Vargas, additional, Vargas, Luis Fernando M Bellatin, additional, Berrocal, Alfredo E, additional, Portocarrero, Manuel Gustavo Leon, additional, Jesus, Felix, additional, and Pena, Romero, additional
- Published
- 2017
- Full Text
- View/download PDF
4. Desarrollo y validación de un cuestionario de satisfacción con el tratamiento en pacientes con artritis reumatoide
- Author
-
Raimon Sanmarti, VERA ORTIZ-SANTAMARIA, Paloma Vela Casasempere, and Rubén Queiro
- Subjects
Rheumatology ,business.industry ,Medicine ,business ,Humanities - Abstract
Objetivo: Desarrollar y validar un instrumento especifico para valorar la satisfaccion con el tratamiento en pacientes afectados de artritis reumatoide (AR). Material y metodos: El cuestionario de satisfaccion se desarrollo utilizando un procedimiento de 3 fases: revision de la literatura medica por parte de expertos en desarrollo de medidas centradas en el paciente, evaluacion de los items seleccionados por parte de 4 expertos en AR en terminos de comprension, formato y aplicabilidad y administracion mediante entrevista personal a un grupo de 14 pacientes con AR en tratamiento con infliximab. La validacion del cuestionario se realizo en una muestra de 180 pacientes con AR que cumplian los criterios del American College of Rheumatology (ACR), mayores de 18 anos y que iniciaron tratamiento con infliximab por insuficiente control de su enfermedad. Los cuestionarios fueron administrados en la visita basal (inicio del tratamiento) y a las 2, 6 y 14 semanas, coincidiendo con las infusiones de infliximab. La validez del cuestionario se evaluo en terminos de validez de constructo (analisis factorial) y validez de contenido. La validez de contenido se evaluo analizando la relacion de la satisfaccion con las distintas variables de efectividad y con el cumplimiento de expectativas creadas antes de iniciar el tratamiento. Resultados: La validacion del cuestionario se realizo en una muestra de 180 pacientes con una edad media (DE) de 52 (13) anos, donde el 80,7% eran mujeres y el 72,4% llevaba mas de 3 anos de evolucion. La puntuacion obtenida del cuestionario de satisfaccion se mostro relacionada con los distintos aspectos que constituyen los criterios ACR, a excepcion de la velocidad de sedimentacion globular (VSG) y la proteina C reactiva (PCR), con el cumplimiento de criterios ACR20, ACR50 y ACR70 y con el cumplimiento de expectativas creadas con el tratamiento (p < 0,01). Discusion: Los resultados obtenidos confirman la validez del cuestionario para evaluar la satisfaccion de los pacientes con el tratamiento para la AR, tanto en condiciones de practica clinica habitual como en condiciones de investigacion.
- Published
- 2006
- Full Text
- View/download PDF
5. Revisión sistemática: ¿el diagnóstico en sí de fibromialgia tiene algún efecto deletéreo sobre el pronóstico?
- Author
-
Raimon Sanmarti, Eliseo Pascual, Loreto Carmona, and Juan Gomez-Reino
- Subjects
medicine.medical_specialty ,Longitudinal study ,business.industry ,Cochrane Library ,medicine.disease ,Review article ,Clinical trial ,Rheumatology ,Healthcare utilization ,Fibromyalgia ,medicine ,Physical therapy ,In patient ,Intensive care medicine ,business ,Resource utilization - Abstract
OBJECTIVE The aim of the present study was to determine the extent to which a label of fibromyalgia (FM) could have a harmful effect on short- and long-term prognosis. METHODS We performed a systematic review using a sensitive search strategy. All studies published in PubMed (since 1961), Embase (since 1991) and Cochrane Library Plus (up to 2005) were selected. The titles and abstracts of articles retrieved from the search were reviewed and clinical trials and studies on prognosis were included. RESULTS Of a total of 650 references retrieved, only 5 were analyzed in detail. Two were longitudinal studies that completely fulfilled the inclusion criteria. These studies were performed in different countries (Canada and the United Kingdom) with sufficient and representative samples. Both studies reported lower resource utilization after a diagnosis of FM. The remaining studies were analyzed in detail, although they did not fulfill the inclusion criteria: there was one longitudinal study to determine the accuracy of the diagnosis of FM, one qualitative study, and a review article. No studies against the hypothesis that a diagnosis of FM worsens prognosis were found. CONCLUSIONS There is no evidence that a diagnosis of FM per se could worsen prognosis in patients with this condition. Indeed, the available evidence, which is of moderate-good quality, suggests that, on the contrary, diagnosis reduces healthcare utilization by patients.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.